VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response. Additional in vitro studies demonstrated the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor, and target multiple cancer cell lines. The findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates while offering a differentiated safety profile designed to reduce systemic toxicity.
This news matters because it represents a critical step forward in the development of next-generation cancer therapies. If BiTAC-ADCs can achieve similar efficacy to existing ADCs but with fewer side effects, they could significantly improve patient outcomes and expand treatment options. The ability to target multiple cancer cell lines suggests broad applicability across different tumor types, which could address a major unmet need in oncology. For investors, the data validation at a prestigious conference like the World ADC Congress may boost confidence in VERAXA's pipeline and technology platform. The company's focus on rigorous quality-by-design principles and its foundation on breakthroughs at the European Molecular Biology Laboratory (EMBL) further underscore its scientific credibility.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. To view the full press release, visit https://ibn.fm/cs8SW. The latest news and updates relating to VRXA are available in the company's newsroom at http://ibn.fm/VRXA.
The announcement was disseminated through BillionDollarClub (BillionDollarClub), a specialized communications platform with a focus on the biggest and brightest companies covered by IBN. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BDC is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public.
For more information, please visit https://www.BillionDollarClub.com. Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: https://www.BillionDollarClub.com/Disclaimer.
